FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025283567> ?p ?o ?g. }

• W2025283567 endingPage "833" @default.
• W2025283567 startingPage "823" @default.
• W2025283567 abstract "Hepatitis B virus (HBV) reactivation during immunosuppression can lead to severe acute hepatitis, fulminant liver failure, and death. Here, we investigated hepatitis B surface antigen (HBsAg) genetic features underlying this phenomenon by analyzing 93 patients: 29 developing HBV reactivation and 64 consecutive patients with chronic HBV infection (as control). HBsAg genetic diversity was analyzed by population-based and ultradeep sequencing (UDS). Before HBV reactivation, 51.7% of patients were isolated hepatitis B core antibody (anti-HBc) positive, 31.0% inactive carriers, 6.9% anti-HBc/anti-HBs (hepatitis B surface antibody) positive, 6.9% isolated anti-HBs positive, and 3.4% had an overt HBV infection. Of HBV-reactivated patients, 51.7% were treated with rituximab, 34.5% with different chemotherapeutics, and 13.8% with corticosteroids only for inflammatory diseases. In total, 75.9% of HBV-reactivated patients (vs. 3.1% of control patients; P < 0.001) carried HBsAg mutations localized in immune-active HBsAg regions. Of the 13 HBsAg mutations found in these patients, 8 of 13 (M103I-L109I-T118K-P120A-Y134H-S143L-D144E-S171F) reside in a major hydrophilic loop (target of neutralizing antibodies [Abs]); some of them are already known to hamper HBsAg recognition by humoral response. The remaining five (C48G-V96A-L175S-G185E-V190A) are localized in class I/II–restricted T-cell epitopes, suggesting a role in HBV escape from T-cell-mediated responses. By UDS, these mutations occurred in HBV-reactivated patients with a median intrapatient prevalence of 73.3% (range, 27.6%-100%) supporting their fixation in the viral population as a predominant species. In control patients carrying such mutations, their median intrapatient prevalence was 4.6% (range, 2.5%-11.3%; P < 0.001). Finally, additional N-linked glycosylation (NLG) sites within the major hydrophilic loop were found in 24.1% of HBV-reactivated patients (vs. 0% of chronic patients; P < 0.001); 5 of 7 patients carrying these sites remained HBsAg negative despite HBV reactivation. NLG can mask immunogenic epitopes, abrogating HBsAg recognition by Abs. Conclusion: HBV reactivation occurs in a wide variety of clinical settings requiring immune-suppressive therapy, and correlates with HBsAg mutations endowed with enhanced capability to evade immune response. This highlights the need for careful patient monitoring in all immunosuppressive settings at reactivation risk and of establishing a prompt therapy to prevent HBV-related clinical complications. (Hepatology 2015;61:823–833)" @default.
• W2025283567 created "2016-06-24" @default.
• W2025283567 creator A5001933436 @default.
• W2025283567 creator A5002994994 @default.
• W2025283567 creator A5004434674 @default.
• W2025283567 creator A5008531739 @default.
• W2025283567 creator A5014527287 @default.
• W2025283567 creator A5020166792 @default.
• W2025283567 creator A5020412439 @default.
• W2025283567 creator A5021429161 @default.
• W2025283567 creator A5023301876 @default.
• W2025283567 creator A5032745315 @default.
• W2025283567 creator A5032926011 @default.
• W2025283567 creator A5045593444 @default.
• W2025283567 creator A5049875479 @default.
• W2025283567 creator A5053389629 @default.
• W2025283567 creator A5059408290 @default.
• W2025283567 creator A5062294081 @default.
• W2025283567 creator A5064623739 @default.
• W2025283567 creator A5070082704 @default.
• W2025283567 creator A5072753411 @default.
• W2025283567 creator A5074692498 @default.
• W2025283567 creator A5076119305 @default.
• W2025283567 creator A5080590367 @default.
• W2025283567 creator A5081041335 @default.
• W2025283567 creator A5083239943 @default.
• W2025283567 creator A5083321816 @default.
• W2025283567 creator A5088510590 @default.
• W2025283567 creator A5091721224 @default.
• W2025283567 date "2015-01-28" @default.
• W2025283567 modified "2023-10-01" @default.
• W2025283567 title "Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression" @default.
• W2025283567 cites W1501443522 @default.
• W2025283567 cites W1553437634 @default.
• W2025283567 cites W1579332351 @default.
• W2025283567 cites W1979792611 @default.
• W2025283567 cites W1983153145 @default.
• W2025283567 cites W2032271472 @default.
• W2025283567 cites W2034231506 @default.
• W2025283567 cites W2044965443 @default.
• W2025283567 cites W2053300706 @default.
• W2025283567 cites W2084152099 @default.
• W2025283567 cites W2098555404 @default.
• W2025283567 cites W2101159020 @default.
• W2025283567 cites W2104098378 @default.
• W2025283567 cites W2122656069 @default.
• W2025283567 cites W2137279862 @default.
• W2025283567 cites W2147134417 @default.
• W2025283567 cites W2161818088 @default.
• W2025283567 cites W2164785014 @default.
• W2025283567 cites W2168560934 @default.
• W2025283567 cites W2339289520 @default.
• W2025283567 cites W2950311394 @default.
• W2025283567 doi "https://doi.org/10.1002/hep.27604" @default.
• W2025283567 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25418031" @default.
• W2025283567 hasPublicationYear "2015" @default.
• W2025283567 type Work @default.
• W2025283567 sameAs 2025283567 @default.
• W2025283567 citedByCount "105" @default.
• W2025283567 countsByYear W20252835672015 @default.
• W2025283567 countsByYear W20252835672016 @default.
• W2025283567 countsByYear W20252835672017 @default.
• W2025283567 countsByYear W20252835672018 @default.
• W2025283567 countsByYear W20252835672019 @default.
• W2025283567 countsByYear W20252835672020 @default.
• W2025283567 countsByYear W20252835672021 @default.
• W2025283567 countsByYear W20252835672022 @default.
• W2025283567 countsByYear W20252835672023 @default.
• W2025283567 crossrefType "journal-article" @default.
• W2025283567 hasAuthorship W2025283567A5001933436 @default.
• W2025283567 hasAuthorship W2025283567A5002994994 @default.
• W2025283567 hasAuthorship W2025283567A5004434674 @default.
• W2025283567 hasAuthorship W2025283567A5008531739 @default.
• W2025283567 hasAuthorship W2025283567A5014527287 @default.
• W2025283567 hasAuthorship W2025283567A5020166792 @default.
• W2025283567 hasAuthorship W2025283567A5020412439 @default.
• W2025283567 hasAuthorship W2025283567A5021429161 @default.
• W2025283567 hasAuthorship W2025283567A5023301876 @default.
• W2025283567 hasAuthorship W2025283567A5032745315 @default.
• W2025283567 hasAuthorship W2025283567A5032926011 @default.
• W2025283567 hasAuthorship W2025283567A5045593444 @default.
• W2025283567 hasAuthorship W2025283567A5049875479 @default.
• W2025283567 hasAuthorship W2025283567A5053389629 @default.
• W2025283567 hasAuthorship W2025283567A5059408290 @default.
• W2025283567 hasAuthorship W2025283567A5062294081 @default.
• W2025283567 hasAuthorship W2025283567A5064623739 @default.
• W2025283567 hasAuthorship W2025283567A5070082704 @default.
• W2025283567 hasAuthorship W2025283567A5072753411 @default.
• W2025283567 hasAuthorship W2025283567A5074692498 @default.
• W2025283567 hasAuthorship W2025283567A5076119305 @default.
• W2025283567 hasAuthorship W2025283567A5080590367 @default.
• W2025283567 hasAuthorship W2025283567A5081041335 @default.
• W2025283567 hasAuthorship W2025283567A5083239943 @default.
• W2025283567 hasAuthorship W2025283567A5083321816 @default.
• W2025283567 hasAuthorship W2025283567A5088510590 @default.
• W2025283567 hasAuthorship W2025283567A5091721224 @default.
• W2025283567 hasBestOaLocation W20252835672 @default.
• W2025283567 hasConcept C147483822 @default.

• next